erlotinib + CB-839

A combination of **erlotinib**, an **epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor**, and **CB-839 (Telaglenastat)**, a **small-molecule inhibitor of glutaminase 1 (GLS-1)**. This combination is being investigated as a metabolic-targeted therapy, particularly in **non-small cell lung cancer (NSCLC)** with EGFR mutations. Erlotinib inhibits EGFR signaling, decreasing glucose uptake and glycolysis, while CB-839 limits glutamine metabolism and impairs glutathione and ATP production. Dual inhibition produces **energetic stress** leading to cell death and tumor regression in preclinical EGFR mutant lung cancer models. The approach seeks to exploit the metabolic dependency of cancer cells on both glucose and glutamine for their survival and proliferation[1][3][5].

Brand names

Tarceva (for erlotinib)Telaglenastat (for CB-839)

Other names

erlotinib and CB-839erlotinib plus CB-839